RedHill Biopharma Ltd. (NASDAQ:RDHL) is trending higher in the market today as the company shares are trading 5.85% or 0.31 points up from last closing price of $5.3, reaching $5.61 at last check. Any clue why there is so much of action in the RDHL stock? The share price has risen in 2 of the last 5 days and is down -23.41% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 12,895 shares, and in total 131895 shares valued at $739931 were seen changing hands compared with 119000 shares valued at $630700 recorded at the previous session. You should take into consideration that a greater volume on higher prices causes bullish signal for the market. It shows the sentiment is in an uptrend and more and more traders want to enter in the RDHL stock.
RedHill Biopharma Ltd. (RDHL) shares have notched a 3-month decline of about -23.41%, but has still tumbled -12.69% year to date. By comparison, the stock sank -36.9% over the past 12 months, while it slipped -10.77% over the 1 month. The company’s market cap is around $186.93M, with its short interest ratio standing at 5.56%.
In the current trading session for RDHL, the stock witnessed two major price actions, it rose to a high of $5.64 and was down as much as $5.35 at one point. The high recorded is very low when compared to their 52-week high which is $5.17. The 52-week high is now at -39.35 distance from current price. Their recent low of $9.2 represents a 7.93% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for RDHL is $21.71, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of RedHill Biopharma Ltd. earned $-1.39 per share in the trailing 12 months and has a P/E ratio of -4.04. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 22.34 and lower compared to the sector’s average of 31.82. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. RDHL also has P/S multiple of 32.65. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 0.25x.
RDHL‘s last price was down -18.79% as compared to the average trading price of 50 days recorded at $6.91 while enlarging the period to 200 trading days, the average closing price was $6.09. At present, there are 35.27 million in the total number of common shares owned by the public and among those 3.58 million shares have been available to trade. The percentage of shares being held by the company management was 15.37% while institutions stake was 23.22%. The company has generated negative returns on equity over the last 12 months (0%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the RDHL stock, there is another set of technicals that should be looked into and considered. Its -4.43% decline from moving average of $5.87 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of RedHill Biopharma Ltd. — 2 analysts rate the stock as a buy with another 1 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $19.33 on shares of RedHill Biopharma Ltd. (NASDAQ:RDHL), which corresponds to 245.86% upside potential than its current market price of $5.61 and implies potential despite the recent advance in the price. However, their current target price has fallen from $19.33 a month ago and is down handily from the consensus target of $20.5 a quarter ago.
Let’s briefly check the hedge fund interest towards RDHL stock. Virtu Financial LLC changed position in the company and now owns 10,138 shares worth $56,874, SEC documents show. ARK Investment Management LLC shored up assets in the stock as 55859.33 shares have been purchased, increasing its stake by 4.5% to 58,373 shares which are currently valued at $327,473. In addition, Creative Planning recently reported that it now owns 385,814 shares making a total of $2,164,417 based on the recent price. This refelects a change of 35.7% in their ownership.